Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
Also Read: Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer PatientsTruist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc. (NASDAQ:CHRS), lowering the price target to $22 from $24.
信託證券 分析師羅賓·卡爾瑙斯卡斯重申了對以下股票的買入評級 Coherus Biosciences, In。納斯達克股票代碼：CHRS），將目標股價從24美元下調至22美元。
Coherus BioSciences has recently agreed to acquire Surface Oncology Inc (NASDAQ:SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
Coherus BioSciences 最近同意收購 表面腫瘤學公司 納斯達克股票代碼：SURF），一家臨床階段的免疫腫瘤學（I-O）公司，開發針對腫瘤微環境的下一代免疫療法。
Following the acquisition, the company will focus on pipeline prioritization of target R&D and reduce expenses, which will enable CHRS to save at least $50 million, the analyst notes.
分析師指出，收購後，該公司將專注於優先考慮目標研發的渠道並減少開支，這將使CHRS能夠節省至少5000萬美元。
Also Read: Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients
另請閱讀： Coherus 的 Toripalimab/Chemo 組合將鼻咽癌患者的死亡風險降低了 37%
The analyst believes the acquisition "makes sense" considering the combination potential of Tori with SURF novel agents and that company is not getting credit for the cost savings due to R&D synergies.
這位分析師認爲，考慮到Tori與SURF新型代理商的合併潛力，此次收購 “有道理”，而且由於研發協同效應，該公司節省的成本並未獲得讚揚。
Coherus will issue shares at $5.2831 per share, equivalent to $40 million plus Surface's net cash (currently expected to be between $20 and $25 million).
Coherus將以每股5.2831美元的價格發行股票，相當於4000萬美元加上Surface的淨現金（目前預計在2000萬至2500萬美元之間）。
In addition, the acquisition adds up to $25 million in cash at closing to CHRS balance sheet, Karnauskas adds.
此外，卡爾瑙斯卡斯補充說，此次收購在CHRS資產負債表收盤時增加了高達2500萬美元的現金。
Overall, the analyst thinks this is the year of transition for the company, with prospects to achieve profitability in 2024 and become cash flow positive.
總體而言，分析師認爲這是公司的過渡年，有望在2024年實現盈利並實現正現金流。
Price Action: CHRS shares are trading lower by 6.90% to $3.85 on the last check Tuesday.
價格走勢： 在週二的最後一張支票上，CHRS股價下跌6.90％，至3.85美元。
譯文內容由第三人軟體翻譯。
